8.14
Schlusskurs vom Vortag:
$7.67
Offen:
$7.61
24-Stunden-Volumen:
1.14M
Relative Volume:
0.81
Marktkapitalisierung:
$464.75M
Einnahmen:
$65,400
Nettoeinkommen (Verlust:
$-46.34M
KGV:
-8.8478
EPS:
-0.92
Netto-Cashflow:
$-38.74M
1W Leistung:
+14.17%
1M Leistung:
-25.39%
6M Leistung:
-27.32%
1J Leistung:
+54.17%
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Vergleichen Sie CRMD mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
CRMD
CorMedix Inc
|
8.14 | 464.75M | 65,400 | -46.34M | -38.74M | -0.92 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-07 | Eingeleitet | Leerink Partners | Outperform |
2025-01-13 | Eingeleitet | D. Boral Capital | Buy |
2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
2021-02-17 | Eingeleitet | Needham | Buy |
2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
2020-09-21 | Eingeleitet | Truist | Buy |
2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
2018-12-06 | Eingeleitet | ROTH Capital | Buy |
2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
2016-11-11 | Bestätigt | FBR & Co. | Outperform |
2016-03-17 | Bestätigt | FBR Capital | Outperform |
2016-03-03 | Eingeleitet | FBR Capital | Outperform |
2015-11-16 | Bestätigt | ROTH Capital | Neutral |
2015-10-29 | Bestätigt | ROTH Capital | Neutral |
2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
2014-12-08 | Bestätigt | ROTH Capital | Buy |
2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
Investors in CorMedix (NASDAQ:CRMD) have seen decent returns of 81% over the past five years - Yahoo Finance
RBC stays bullish on CorMedix as Q1 preliminary revenue reassures on near-term - Yahoo Finance
CorMedix expects Q1 sales above estimates, lifts H1 outlook - MSN
CorMedix reports preliminary Q1 revenue $39M, consensus $32.2M. - TipRanks
CorMedix at Needham Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
CorMedix at Needham Conference: Strategic Growth and Challenges - Investing.com
CorMedix Stock Rises After Preliminary Q1 Results Exceeds Expectations: Retail’s Elated - MSN
CRMD Soars 19.40% as CorMedix Announces Preliminary Q1 Results and Raises H1 Guidance, But Will the Momentum Continue? - RagingBull
CorMedix Inc. Raises Financial Guidance for First Half of 2025 - MarketScreener
CorMedix Sees Q1 Net Sales of $39 Million; Boosts H1 Net Sales Guidance - MarketScreener
Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance - The Manila Times
CorMedix Logs Q1 Prel. Revenue Of $39 Mln - Nasdaq
CorMedix reports strong preliminary Q1 revenue and EBITDA - Investing.com
CorMedix Smashes Expectations: $39M Q1 Revenue and Massive Guidance Boost Signals Growth Acceleration - Stock Titan
CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference - The Manila Times
CorMedix CEO Sets Stage for Strategic Updates at Elite Needham Healthcare Conference - Stock Titan
CorMedix Inc. (NASDAQ:CRMD) Q4 2024 Earnings Call Transcript - Insider Monkey
CorMedix Inc. Reports Record Q4 Earnings and Growth - TipRanks
CorMedix: A Fair-Priced Biotech Company With A Bright Future - Seeking Alpha
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of ... - Bluefield Daily Telegraph
Institutions along with individual investors who hold considerable shares inCorMedix Inc. (NASDAQ:CRMD) come under pressure; lose 35% of holdings value - Yahoo Finance
CorMedix targets $50M-$60M revenue for H1 2025 with DefenCath growth - MSN
CorMedix Inc.'s (NASDAQ:CRMD) 35% loss last week hit both individual investors who own 56% as well as institutions - simplywall.st
Lost Money on CorMedix Inc.(CRMD)? Contact Levi & Korsinsky Regarding an Ongoing Investigation - ACCESS Newswire
Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors - GlobeNewswire
The Hidden Risks Behind CorMedix's First Profitable Quarter (NASDAQ:CRMD) - Seeking Alpha
CorMedix Inc (NASDAQ:CRMD) Order Delay - FXDailyReport.Com
Long Term Trading Analysis for (CRMD) - news.stocktradersdaily.com
INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC - GlobeNewswire
CorMedix Inc. (CRMD) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates - Louisiana First News
Cormedix Inc (CRMD) Q4 2024 Earnings Call Highlights: A Profitable Quarter Amidst Strategic ... By GuruFocus - Investing.com Canada
CorMedix Inc. Achieves Profitability with DefenCath Launch - TipRanks
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target By Investing.com - Investing.com Australia
CorMedix: Q4 Earnings Snapshot - MySA
Rodman & Renshaw reiterates CorMedix stock Buy rating, $20 target - Investing.com
CorMedix (CRMD) Q4 2024 Earnings Call Transcript - AOL.com
CorMedix earnings beat by $0.05, revenue topped estimates - Investing.com Canada
Needham Cuts CorMedix's Price Target to $12 from $18, Keeps Buy Rating - MarketScreener
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It - Asianet Newsable
Cormedix: Positive Outlook with Strategic Advancements and Strong Financial Performance - TipRanks
CorMedix Inc. (CRMD) Takes a Hit: What’s Behind the 31% Plunge? - RagingBull
Nasdaq Gains 50 Points; US New Home Sales Rise In February - Benzinga
CorMedix Stock Loses Almost A Third Of Its Market Cap After Downbeat H1 Revenue Outlook – But Retail Shrugs It Off - MSN
Earnings call transcript: CorMedix Q4 2024 reports first profit, stock plunges - Investing.com Australia
CorMedix shares tumble after order delay By Investing.com - Investing.com Philippines
CorMedix shares tumble after order delay - Investing.com
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):